Crispr Therapeutics shares tumble after significant earnings miss
John C. Malone, a significant shareholder of Atlanta Braves Holdings, Inc. (NASDAQ:BATRA), recently purchased 1,135 shares of the company’s Series A Common Stock. The transaction, which took place on March 14, 2025, was executed at a weighted average price of $42.00 per share, totaling approximately $47,670. Following this acquisition, Malone holds 215,976 shares directly. The stock currently trades at $42.85, with a market capitalization of $2.66 billion. According to InvestingPro analysis, BATRA generally trades with low price volatility, making it an interesting case for stability-focused investors.
The purchase was conducted through a broker dealer, with the price range for the transaction being between $41.97 and $42.00 per share, as noted in the filing. Additionally, Malone indirectly holds 10,177 shares through the Leslie A. Malone 1995 Revocable Trust, for which he disclaims beneficial ownership. With an overall Financial Health Score labeled as ’WEAK’ by InvestingPro, investors might want to conduct thorough due diligence - detailed insights are available in the comprehensive Pro Research Report, which covers what really matters about this and 1,400+ other top stocks.
This acquisition reflects Malone’s continued investment in Atlanta Braves Holdings, a company classified under the Amusement & Recreation Services industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.